TSE:CPH Cipher Pharmaceuticals (CPH) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free CPH Stock Alerts C$8.90 -0.37 (-3.99%) (As of 03/28/2024 ET) Add Compare Share Share Today's RangeC$8.76▼C$9.4350-Day RangeC$5.60▼C$9.5052-Week RangeC$3.11▼C$9.98Volume59,311 shsAverage Volume38,791 shsMarket CapitalizationC$213.51 millionP/E Ratio8.17Dividend YieldN/APrice TargetC$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlines Get Cipher Pharmaceuticals alerts: Email Address Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one About Cipher Pharmaceuticals Stock (TSE:CPH)Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne; Lipofe indicated as adjunctive therapy to diet to reduce triglycerides in adult patients with severe hypertriglyceridemia; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.Read More CPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPH Stock News HeadlinesMarch 28, 2024 | theglobeandmail.comCipher Pharmaceuticals: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (CPH)March 17, 2024 | seekingalpha.comCipher Pharmaceuticals (CPHRF) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 17, 2024 | investing.comEarnings call: Cipher Pharmaceuticals outlines growth and financialsJanuary 5, 2024 | morningstar.comCipher Pharmaceuticals Inc CPHJanuary 3, 2024 | finance.yahoo.comCipher Pharmaceuticals Inc (PHE.MU)November 24, 2023 | finance.yahoo.comCipher Pharmaceuticals Announces Change of AuditorNovember 24, 2023 | benzinga.comCipher Pharmaceuticals Stock (OTC:CPHRF) Dividends: History, Yield and DatesMarch 29, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…November 15, 2023 | finance.yahoo.comCipher Pharmaceuticals Inc.'s (TSE:CPH) 23% gain last week benefited both individual investors who own 56% as well as insidersOctober 27, 2023 | finance.yahoo.comCipher Pharmaceuticals Schedules Q3 2023 Earnings Release and Conference CallSeptember 5, 2023 | finance.yahoo.comCipher Pharmaceuticals Announces Intention to Commence Substantial Issuer Bid, Aggregate Price up to $6 Million Canadian DollarsAugust 10, 2023 | finance.yahoo.comCipher Pharmaceuticals Releases Q2 2023 Results, Announces Launch of Epuris in MexicoJuly 28, 2023 | finance.yahoo.comCipher Pharmaceuticals Schedules Q2 2023 Earnings Release and Conference CallJuly 5, 2023 | finance.yahoo.comCipher Partner, Moberg Pharma Announces Approval for MOB-015 in the European UnionJune 21, 2023 | finance.yahoo.comCipher Pharmaceuticals Announces Results of Annual and Special Meeting of ShareholdersMay 4, 2023 | finance.yahoo.comCipher Pharmaceuticals Schedules Q1 2023 Earnings Release and Conference CallApril 26, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc flat on Tuesday (CPH)April 20, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc flat on Thursday (CPH)April 18, 2023 | finanznachrichten.deBloom Burton & Co. Inc.: Cipher Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 18, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc up on Tuesday (CPH)April 18, 2023 | finance.yahoo.comCipher Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 14, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc up on Friday (CPH)April 10, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc down on Monday (CPH)April 6, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc down on Wednesday (CPH)March 19, 2023 | seekingalpha.comCipher Pharmaceuticals Non-GAAP EPS of -$0.12March 16, 2023 | finance.yahoo.comCipher Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial ResultsSee More Headlines Receive CPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today3/29/2024Next Earnings (Estimated)5/09/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:CPH Previous SymbolTSE:DND CUSIPN/A CIKN/A Webwww.cipherpharma.com Phone+1-905-6025840FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price TargetC$8.00 High Stock Price TargetC$8.00 Low Stock Price TargetC$8.00 Potential Upside/Downside-10.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)C$1.09 Trailing P/E Ratio8.17 Forward P/E Ratio14.46 P/E GrowthN/ANet IncomeC$20.38 million Net Margins96.32% Pretax MarginN/A Return on Equity28.19% Return on Assets8.06% Debt Debt-to-Equity Ratio0.44 Current Ratio9.19 Quick Ratio2.67 Sales & Book Value Annual SalesC$21.16 million Price / Sales10.09 Cash FlowC$2.52 per share Price / Cash Flow3.53 Book ValueC$3.36 per share Price / Book2.65Miscellaneous Outstanding Shares23,990,000Free FloatN/AMarket CapC$213.51 million OptionableNot Optionable Beta0.97 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Craig J. MullInterim CEO & Chairman of the BoardMr. Bryan JacobsChief Financial OfficerDr. Diane GajewczykVice President of Scientific & Medical AffairsMr. Emilio PrestiDirector of Sales & MarketingKey CompetitorsICC LabsCVE:ICCESSA PharmaCVE:EPIRIV CapitalTSE:RIVLeaf MobileTSE:LEAFSupreme CannabisTSE:FIREView All Competitors CPH Stock Analysis - Frequently Asked Questions Should I buy or sell Cipher Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPH shares. View CPH analyst ratings or view top-rated stocks. What is Cipher Pharmaceuticals' stock price target for 2024? 1 brokerages have issued 12-month price objectives for Cipher Pharmaceuticals' stock. Their CPH share price targets range from C$8.00 to C$8.00. On average, they predict the company's stock price to reach C$8.00 in the next twelve months. This suggests that the stock has a possible downside of 10.1%. View analysts price targets for CPH or view top-rated stocks among Wall Street analysts. How have CPH shares performed in 2024? Cipher Pharmaceuticals' stock was trading at C$5.54 on January 1st, 2024. Since then, CPH stock has increased by 60.6% and is now trading at C$8.90. View the best growth stocks for 2024 here. When is Cipher Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CPH earnings forecast. How were Cipher Pharmaceuticals' earnings last quarter? Cipher Pharmaceuticals Inc. (TSE:CPH) issued its quarterly earnings results on Thursday, March, 14th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.26. The company earned $6.70 million during the quarter, compared to analyst estimates of $7.31 million. Cipher Pharmaceuticals had a net margin of 96.32% and a trailing twelve-month return on equity of 28.19%. What other stocks do shareholders of Cipher Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cipher Pharmaceuticals investors own include Cipher Pharmaceuticals (CPHRF), Bellatrix Exploration (BXE), Aurora Cannabis (ACB), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Catalyst Biosciences (CBIO), Crescent Point Energy (CPG) and Enbridge (ENB). How do I buy shares of Cipher Pharmaceuticals? Shares of CPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:CPH) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cipher Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.